Short Interest in PURE Bioscience, Inc. (OTCMKTS:PURE) Declines By 14.7%
Short Interest in PURE Bioscience, Inc. (OTCMKTS:PURE) Declines By 14.7%
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) saw a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 6,400 shares, a decrease of 14.7% from the March 31st total of 7,500 shares. Based on an average daily volume of 131,500 shares, the days-to-cover ratio is presently 0.0 days.
Pure Bioscience，Inc.(场外市场代码：Pure-Get Rating)在4月份看到空头股数的销量大幅下降。截至4月15日，空头股数共有6,400股，较3月31日的7,500股减少14.7%。以日均成交量131,500股计算，目前天数与回补比率为0.0天。
PURE Bioscience Price Performance
纯生物科学性价比
Shares of PURE stock opened at $0.09 on Friday. The firm's 50-day moving average is $0.13 and its 200-day moving average is $0.14. PURE Bioscience has a 52-week low of $0.07 and a 52-week high of $0.24.
纯股票周五开盘报0.09美元。该公司的50日移动均线切入位在0.13美元，200日移动均线切入位在0.14美元。Pure Bioscience的52周低点为0.07美元，52周高位为0.24美元。
PURE Bioscience (OTCMKTS:PURE – Get Rating) last issued its earnings results on Friday, March 17th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.40 million during the quarter. PURE Bioscience had a negative net margin of 228.72% and a negative return on equity of 142.15%.
Pure Bioscience(OTCMKTS：Pure-Get Rating)上一次发布财报是在3月17日(星期五)。该公司公布了该季度每股收益(EPS)(0.01美元)。该公司本季度的收入为40万美元。纯生物科学公司的净利润率为负228.72%，净资产回报率为负142.15%。
Institutional Investors Weigh In On PURE Bioscience
机构投资者参与纯生物科学
An institutional investor recently bought a new position in PURE Bioscience stock. IFG Advisory LLC acquired a new position in shares of PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 809,809 shares of the company's stock, valued at approximately $161,000. IFG Advisory LLC owned about 0.92% of PURE Bioscience as of its most recent SEC filing. 0.92% of the stock is currently owned by institutional investors and hedge funds.
一家机构投资者最近买入了一只新的纯生物科学股票头寸。根据IFG Consulting LLC最近提交给美国证券交易委员会(SEC)的13F文件，该公司在第三季度收购了Pure Bioscience，Inc.(场外交易市场代码：Pure-Get Rating)的股票。该公司收购了809,809股公司股票，价值约161,000美元。截至最近提交的美国证券交易委员会申请文件，IFG Consulting LLC持有Pure Bioscience约0.92%的股份。该股目前由机构投资者和对冲基金持有0.92%。
PURE Bioscience Company Profile
Pure Bioscience公司简介
(Get Rating)
(获取评级)
PURE Bioscience, Inc engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.
Pure Bioscience，Inc.致力于发现、开发和商业化用于病原体和卫生控制的专有抗菌产品。它提供以柠檬酸二氢银为基础的消毒和消毒产品。该公司由Michael L.Krall于1992年8月24日创立，总部设在加利福尼亚州的兰乔库卡蒙加。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- 免费获取StockNews.com关于纯生物科学的研究报告(PURE)
- 市场回顾周-4/24-4/28
- 如何投资今年最受欢迎的食品杂货股
- 阵列技术将太阳耀斑带到2023年收益预测
- 利率上升前最适合投资的银行股
- 如何投资农田：7个简单的方法
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得《纯生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pure Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。